{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-010456","form_type":"8-K","ticker":"BIAF","cik":"0001712762","company_name":"bioAffinity Technologies, Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.174214+00:00","generated_at":"2026-06-17T07:06:48.872714+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"bioAffinity reports FY2022 net loss $8.2M ($1.81/sh), revenue $5K; cash $11.4M, plans pivotal trial 2023","bullets":["FY2022 net loss $8.2M ($1.81/sh) vs $6.3M ($2.36/sh) in 2021; revenue $5K from CyPath Lung LDT.","Q4 2022 net loss $1.7M, revenue $2,500; cash and equivalents $11.4M as of Dec 31, 2022.","Raised net $6.0M from IPO in Sep 2022; additional $7.8M from warrant/option exercises.","CyPath Lung clinical validation: 92% sensitivity, 87% specificity in high-risk patients; AUC 94%.","Pivotal trial for FDA clearance to recruit 1,800 patients starting in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-010456","json":"https://secwatch.observer/filing/0001493152-23-010456.json","markdown":"https://secwatch.observer/filing/0001493152-23-010456.md","text":"https://secwatch.observer/filing/0001493152-23-010456.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1712762/000149315223010456/0001493152-23-010456-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1712762/000149315223010456/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:06:48.872714+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e9c953e9da47cabb11281aee84ef1daa11d14108","claim":"bioAffinity Technologies, Inc. reported the three and 12 months ended December 31, 2022 results: revenue approximately $2,500, net income Net loss for the fourth quarter of 2022 was $1.7 million.","evidence_excerpt":"Revenue for the fourth quarter of 2022 was approximately $2,500, compared with no revenue for the prior-year period.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1712762/000149315223010456/0001493152-23-010456-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and 12 months ended December 31, 2022"},{"label":"Revenue","value":"approximately $2,500"},{"label":"Net income","value":"Net loss for the fourth quarter of 2022 was $1.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}